{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:40:22Z","timestamp":1791909622853,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.antiviral.2022.105348","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T22:22:35Z","timestamp":1653603755000},"page":"105348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D"],"prefix":"10.1016","volume":"203","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-5951","authenticated-orcid":false,"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105348_bib1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.22790","article-title":"The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains","volume":"49","author":"Amini-Bavil-Olyaee","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105348_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3449","article-title":"Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma","volume":"13","author":"Arzumanyan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2022.105348_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jhep.2019.07.010","article-title":"In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"71","author":"Blackard","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105348_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/jhep.2003.50012","article-title":"Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro","volume":"37","author":"Chen","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105348_bib5","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105348_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2022.105348_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2893.2002.00304.x","article-title":"World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants","volume":"9","author":"Funk","year":"2002","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105348_bib8","article-title":"HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals","volume":"186","author":"Glebe","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/liv.14241","article-title":"Entecavir resistance mutations rtL180M\/T184L\/M204V combined with rtA200V lead to tenofovir resistance","volume":"40","author":"Jiang","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105348_bib10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.antiviral.2022.105348_bib11","article-title":"In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates","volume":"18","author":"Liu","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.antiviral.2022.105348_bib12","doi-asserted-by":"crossref","first-page":"19804","DOI":"10.1074\/jbc.RA119.009435","article-title":"The MOV10 helicase restricts hepatitis B virus replication by inhibiting viral reverse transcription","volume":"294","author":"Liu","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2022.105348_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jvh.13397","article-title":"Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance","volume":"28","author":"Liu","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105348_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105348_bib15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/liv.12343","article-title":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D","volume":"34","author":"Liu","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105348_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104579","article-title":"Investigation of hepatitis B virus (HBV) rtS78T\/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside\/nucleotide analogue treatment","volume":"170","author":"Luo","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.antiviral.2012.09.014","article-title":"Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy","volume":"96","author":"Mirandola","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12688\/wellcomeopenres.15992.1","article-title":"Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms","volume":"5","author":"Mokaya","year":"2020","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105348_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2012.12.007","article-title":"The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir","volume":"97","author":"Qin","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib21","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1128\/JVI.00819-11","article-title":"Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity","volume":"85","author":"Qin","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105348_bib22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","volume":"17","author":"Revill","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105348_bib23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2022.105348_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105348_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.29609","article-title":"Hepatitis B virus sensitivity to interferon-\u03b1 in hepatocytes is more associated with cellular interferon response than with viral genotype","volume":"67","author":"Shen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105348_bib26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jhep.2017.03.027","article-title":"Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy","volume":"67","author":"Shirvani-Dastgerdi","year":"2017","journal-title":"J. Hepatol"},{"key":"10.1016\/j.antiviral.2022.105348_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2022.105348_bib28","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1128\/JVI.01293-16","article-title":"In vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes","volume":"90","author":"Sozzi","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105348_bib29","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1128\/JVI.78.16.8524-8535.2004","article-title":"Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants","volume":"78","author":"Tacke","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105348_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/atm.2016.09.19","article-title":"Treatment for hepatitis B in patients with drug resistance","volume":"4","author":"Tacke","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.antiviral.2022.105348_bib31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105348_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2008.09.068","article-title":"In vitro characterization of viral fitness of therapy-resistant hepatitis B variants","volume":"136","author":"Villet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105348_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105348_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2016.09.005","article-title":"Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA","volume":"66","author":"Xiang","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105348_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2018.07.021","article-title":"Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient","volume":"255","author":"Zhang","year":"2018","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2022.105348_bib36","article-title":"Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:37:00Z","timestamp":1759063020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"alternative-id":["S0166354222001176"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105348","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105348"}}